Allogeneic bone marrow or stem cell transplantation

Specialty: Hematology


IVIG is not recommended for routine use after HSCT. IVIG may be considered in exceptional cases:

1) Active CMV-induced pneumonitis following transplantation.

2) High risk allogeneic stem cell transplantation (e.g. If hypogammaglobulinemia) for prevention of GVHD.


1) No recommended dose or duration listed; use in conjunction with appropriate antiviral medication.

2) 0 .4 g/kg weekly, starting one day before transplantation and continuing to day 100 post-transplant.